CPHI Think Tank 2024: A Premier Gathering for Pharmaceutical Innovation and Industrial Development
Amid the global surge in pharmaceutical industry development, innovative drugs are evolving and iterating at an unprecedented pace. In an era characterized by both challenges and opportunities, accelerating the R&D of next-generation innovative drugs and advancing the commercialization of existing products have become core drivers for the sustained progress of the pharmaceutical sector. This not only requires companies to accurately identify unmet clinical needs and establish a solid foundation of quality from the outset of R&D, but also to actively explore differentiated, cutting-edge pathways and build an open, collaborative ecosystem to stimulate new forms of innovative momentum within the industry.
To strengthen cross-industry exchange and cooperation, and to support the innovative development of China’s new drug R&D industry,October 31–November 1, 2024，“CPHI Insights — The 4th Drug Innovation and Industry Development Conference 2024"will be inCrowne Plaza Shanghai St. NoahEmbarking on a New Journey. This year’s conference will undergo a major upgrade, themed “Innovation & Research Empowering New Horizons · Driving the Future" as the theme, integratingTumor Immunotherapy, Outbound Business Development (BD) Partnerships for Innovative Drugs, Advanced Therapies, Small-Molecule Innovative Drugs, Biologics Process Development and Commercialization, Drug-Device Combination Products, Biologic Packaginghotspots such as , bringing together1000Remaining professionals in the field of pharmaceutical innovation will diagnose the pulse of China’s pharmaceutical innovation and contribute to the coordinated development across industries.
Time:October 31–November 1, 2024
Location:Crowne Plaza Shanghai Noah's Ark
Organizational Structure
Guiding Organizations: Shanghai Biomedical Science and Technology Industry Promotion Center
Organizer: China Chamber of Commerce for Import and Export of Medicines and Health Products, Shanghai Informa Markets Exhibition Co., Ltd., Shanghai Boying E-commerce Co., Ltd.
Supporting Organizations: Fudan University Zhangjiang Institute, Shanghai Biomedical Industry Association
Strategic Cooperation Partner: Shanghai Biopharmaceutical Investment and Financing Development Alliance, Shanghai Food and Drug Packaging Materials Testing Institute, Shanghai Pharmaceutical Industry Association, Xiaobaofu (Shanghai) Medical Technology Co., Ltd., School of Pharmacy, Shanghai Jiao Tong University, Guangdong MedValley, Yihong Business School, Guosheng Capital · Baoshan Medicine Valley, Shanghai Pudong Life Science Industry Development Co., Ltd.
Gathering of Luminaries, Forging Ahead Together
2024 CPHI Thought Sharing Session
AudiencePre-registrationHot and Happening!
Scan the QR code now.Complete Pre-registration
Join this pharmaceutical feast!
October 31
Main Forum: Innovation and Research Empowering Renewal · Driving the Future
09:00-09:20
Address
Guests of Honor Invited by the Host and Co-Organizers
09:20-09:50
Keynote Address
Academician Expert
09:50-10:20
Keynote Address
Academicians and Experts
10:20-10:40
Tea Break and Networking
10:40-11:10
Keynote Address
The Development of Innovative Drugs from the Perspective of Patents and Clinical Trials
Chen Daming
Deputy Director, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences
11:10-11:40
Keynote Speech
The Current State and Turning Point in the Commercialization of China’s Innovative Drugs
Liu Qian
General Manager, Respiratory and Gastrointestinal Business Unit, AstraZeneca
11:40-12:10
Keynote Address
Innovative Development and Regulatory Considerations for Drug-Device Combination Products
Gong Qianfei
Deputy Director of the Business Management Department, Shanghai Center for Drug Evaluation and Inspection
Topic 1: Frontier Innovative Technologies and Clinical Practice in Oncology Drug Evaluation
Special Topic Partners: Shanghai Biomedical Technology Industry Promotion Center, Fudan University Zhangjiang Research Institute
13:30-14:00
Discovery of Novel Targets and Development of Anti-Tumor Drugs
TBD
14:00-14:30
Translational Strategies and Application Examples in Antitumor Drug Development
Wen Danyi
Chairman and CEO of Shanghai Lead Biology & Technology Co., Ltd.
14:30-15:00
Progress in New Drug Development and Clinical Practice for Pancreatic Cancer
Gao Heli
Associate Chief Physician, Fudan University Shanghai Cancer Center
15:00-15:20
Tea Break & Networking
15:20-15:40
Keynote Address
Exploration and Practice of 3D Bioprinting in the Field of Tumor Drug Evaluation
Tang Min
Young Researcher, Shanghai University of Traditional Chinese Medicine
15:40-16:00
Keynote Address
Practical Experience and Protocol Design Strategies for Clinical Trials of Novel Drugs in Lung Cancer
He Yayi
Chief Physician, Department of Medical Oncology, Shanghai Pulmonary Hospital
16:00-16:20
Keynote Speech
Exploration and Practice of the Hospital-Enterprise Collaborative Innovation Model for the Clinical Translation of Novel Anti-Tumor Drugs
Mannitol
Associate Chief Physician, Department of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University
16:20-17:00
Keynote Speech
Roundtable Discussion: Frontier Innovative Technologies in Oncology Drug Evaluation and Future Trends in Clinical Practice
Topic 2: Global Expansion of Innovative Drugs – Internationalization and BD Collaboration Strategies
13:30-13:35
Host's Opening Remarks
Tian Jikang
Deputy Secretary-General of the Yangtze River Delta Medical Innovation and Development Alliance
13:35-13:40
Forum Address
Wang Maochun
Vice President of the China Chamber of Commerce for Import and Export of Medicines & Health Products
13:40-14:10
Interpretation of the Internationalization Development of Shanghai’s Innovative Drug Industry and Related Support Policies
Li Jizong
Director of the Shanghai Biomedical Science and Technology Development Center
14:10-14:40
Hutchmed’s Path to Globalizing Its Independently Developed Innovative Drugs
Cui Yiling
Executive Vice President of HUTCHMED
14:40-15:10
Keynote Address
CAR-T Global Expansion Strategy and Experience Sharing (Draft)
Martial Arts
General Manager, Legend China
15:10-15:30
Keynote Address
Tea Break and Networking
15:30-16:00
Keynote Address
Current Trends in Business Development and Gan & Lee's Strategic move for Novel Biologics Development for Diabetes and Obesity Management.
Dr. Dhaval Jasraj Soneji,Ph.D.
Director of Key Accounts, International Division, Gan & Lee Pharmaceuticals Co., Ltd.
16:00-16:30
Considerations for the Global Expansion of Innovative Drugs Based on Regulatory Requirements in Different Countries
Sun Hualong
Chief Strategy Officer of Colinlicon, Vice Chair of the Data Science Committee of the Drug Information Association (DIA)
16:30-17:30
Roundtable Discussion: From Humble Beginnings to Metamorphosis—Envisioning the Next Decade of Chinese Innovative Drugs Going Global
Host
Tian Jikang,Deputy Secretary-General of the Yangtze River Delta Pharmaceutical Innovation and Development Alliance
Panelists
Li Jizong, Director of the Shanghai Biomedical Technology Development Center
Cui Yiling, Executive Vice President of Hutchmed
Wu Shu, General Manager of Legend China
Sun Hualong, Chief Strategy Officer at Kelin Likang and Vice Chair of the Data Science Committee of the Drug Information Association (DIA)
Kong Liang, Vice President of Clinical Operations at Lixin Pharma
Topic 3: Advanced Therapy Innovation Forum
13:30-14:00
Keynote Speech
AAV Vector-Based Broad-Spectrum Vision Restoration Gene Therapy (Provisional Title)
Tan Chang
Vice President, Suzhou Xingming Youjian Biotechnology Co., Ltd.
14:00-14:30
Keynote Address
Progress in the Development of iPSC-Derived Cell Therapies
Dong Chengyou
Quality Director, Anhui Zhongsheng Suyuan Biotechnology Co., Ltd.
14:30-15:00
Gene Therapy for ALS
Zhang Li
Head of Neuromuscular Diseases, Biogen Medical Affairs
15:00-15:20
Tea Break and Networking
15:20-15:50
Research Progress on Innovative CAR-T Products
Lou Xiaoyan
Deputy General Manager, Shanghai Ucardi Intelligent Manufacturing Life Technology Co., Ltd.
15:50-16:20
Development and Challenges of Gene Therapy Drugs for Ocular Neovascular Diseases
Luo Guangzuo
Founder and Chief Scientific Officer, Nanjing Bestow Biotechnology Co., Ltd.
16:20-16:50
Immunotherapy and Innovative Vaccines
Wang Jianxin
General Manager, Jiangsu Xinshengyuan Biotechnology Co., Ltd.
16:50-17:30
Roundtable Discussion: Pipelines and Future Commercialization Strategies in Cell and Gene Therapy (Proposed)
November 1
Topic 4: Small-Molecule New Drugs
09:00-09:30
Keynote Address
From New Drug Development to Commercial Manufacturing: CMC Challenges and Strategies (Proposed)
Liu Bo
Vice President, Hutchison MediPharma (Shanghai) Co., Ltd.
09:30-10:00
Keynote Address
Progress and Prospects in Small-Molecule Drug Development
Yan Shuizhong
Chief Operating Officer, Global R&D, Zai Lab
10:00-10:30
Keynote Speech
Process Analytical Technology Accelerates Drug Development, Optimization, and Scale-Up
Zhang Rui
Technical Director, Mettler Toledo Technology (China) Co., Ltd.
10:30-11:00
Tea Break and Networking
11:00-11:30
Application of Nucleic Acid-Encoded Compound Libraries in the Development of Covalent Small-Molecule Drugs
Lu Xiaojie
Principal Investigator, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
11:30-12:00
Development Strategies for Undruggable Targets in Key Tumor Signaling Pathways
Yi Wang
Chief Medical Officer and Head of Global R&D, Jacobio Pharmaceuticals
12:00-12:30
Research on Anti-Digestive Tract Tumor Drugs
Zhang Ao
Dean, School of Pharmacy, Shanghai Jiao Tong University
12:30-13:30
Lunch Break
13:30-14:00
AI-Driven Small Molecule Drug Design
Long Wei
Founder and CEO of Beijing Zhiweituo Pharmaceutical Technology Co., Ltd.
14:00-14:30
Targeting Novel GPCRs Expressed on pDCs for the Treatment of IgG4-Related Disease
Fan Guohuang
Chairman & CEO of Amefab Biopharmaceutical Technology Co., Ltd.
14:30-15:00
Proteolysis-Targeting Chimeras (PROTACs): From Mechanistic Principles to Clinical Applications
Zeng Li
CEO of Hejing Medical
15:00-15:30
Tea Break & Networking
15:30-16:00
Discussion on Key Issues in CMC R&D and Licensing for Innovative Drugs
Wang Zhixuan
Sanofi China R&D Center, Director of CMC Business & External Partnerships
16:00-16:30
Design, Discovery, and Differentiated Portfolio Strategy for First-in-Class (FIC) Drugs
TBD
16:30-17:20
Roundtable Discussion: Where Are the Breakthroughs in Small-Molecule New Drug Development in the Era of Biologics?
Topic 5: Process Development and Commercial Manufacturing of Biologics
Special Topic Partners: Guangdong Medical Valley, Yihong Business School
09:00-09:30
Keynote Speech
Impact of PD-1 Gene Knockout on the Safety and Efficacy of CAR-T Cells
Lin Yiguang
Chief Scientist, Guangzhou Anjie Biomedical Technology Co., Ltd.
09:30-10:00
Keynote Address
Reflections on the Commercialization Prospects of CAR-T Cell Therapies
Yang Lin
Chairman of Boshengji
10:00-10:30
Keynote Speech
Drug R&D and Global Expansion Trends
Chen Zhaorong
Chief Medical Officer, Duoma Pharmaceutical Technology (Suzhou) Co., Ltd.
10:30-11:00
Tea Break & Networking
11:00-11:30
Process and Manufacturing of Cell and Gene Therapy Drugs
TBD
11:30-12:00
Application of Universal CAR-T in the Treatment of Autoimmune Diseases
Tan Binghe
Vice President of CMC at Bangyao Biotechnology
12:00-13:30
Lunch Break
13:30-14:00
XDCs and PROTAC Molecules Address the Challenge of Undruggable Targets
Xiang Shaoyun
CEO of Hangzhou Duoyu Biotechnology Co., Ltd.
14:00-14:30
Intelligent Data System for Biopharmaceutical Manufacturing Operations
Li Shude
Chief Manufacturing Officer, China Resources Biopharmaceuticals
14:30-15:00
Technical Key Points in the Process Development of mRNA Drug Formulations
Li Xiang
Senior Manager, Formulations, Huadong Medicine
15:00-15:30
Tea Break & Networking
15:30-16:00
Process Development and Manufacturing of Bioconjugate Drugs
Dai Xudong
Director, Conjugated Drug Process Development Department, WuXi XDC
16:00-16:30
Supply Chain Management under the Commercialization Model of Biologics
Yu Fei
Senior Director of Supply Chain, Henlius
16:30-17:10
Roundtable Discussion: Key Considerations and Supply Chain Management Strategies in the Commercialization of Next-Generation Biologics
Topic 6: Drug Packaging and Drug Delivery Devices
Special Topic Partner: Shanghai Institute of Food and Drug Packaging Materials Testing
09:00-09:45
Keynote Speech
Regulatory Framework for Biological Products and Their Packaging
Li Jianping
Senior Director of Compliance Monitoring, Shanghai Junshi Biosciences Co., Ltd.
09:45-10:25
Keynote Address
Novel Drug Delivery Devices and Regulatory Registration in Various Countries
Guo Rong
Vice President of R&D, Shanghai New Shine Paike Medical Technology Co., Ltd.
10:25-10:55
Keynote Speech
Tea Break & Networking
10:55-11:40
Development Trends and Challenges in Formulation Development and Administration Routes of GLP-1 Therapeutics
Wang Yefei
Vice President, Pharmaceutical Sciences Department, Hongyun Huaning (Hangzhou) Biopharmaceutical Co., Ltd.
11:40-13:30
Lunch Break
13:30-14:15
Requirements and Challenges for Drug Packaging Materials in the Low-Temperature Storage of Biologics
Zhang Fangfang
Director, Quality and Scientific Research Management Office, Shanghai Institute of Food and Drug Packaging Materials Testing
14:15-14:55
Comprehensive Solutions for Novel Polymer Pre-filled Syringe Injectables
Yin Fumin
General Manager, Nanjing Butterfly Pharmaceutical Packaging Materials Co., Ltd.
14:55-15:25
Tea Break & Networking
15:25-16:05
Change Management of Pharmaceutical Packaging Materials in Product Lifecycle Management
Liao Ping
Drug Review Inspector, Department of Innovation and Regulatory Science Development, Shanghai Center for Drug Evaluation and Inspection
Topic 7: Global Expansion of Innovative Drugs – Regulatory Registration Strategy
Special Partner: PharmaOnline
09:00-09:30
Opportunities and Challenges: Overseas Expansion Strategies and Building Internationalization Capabilities for Innovative Pharmaceutical Companies
Anjin Biotech09:30-10:00
Japan Market and Registration Strategy
Dr. Deepak Hegde
General Manager & China Site Head, Cipla (Jiangsu) Pharmaceutical Co. Ltd.
10:00-10:30
Registration and Market Status of Innovative Drugs (Europe)
TBD
10:30-11:00
Tea Break & Networking
11:00-11:30
Introduction to Regulatory Affairs in Russia and Eurasian Economies
Hu Jiawei
Head of Regulatory Affairs, Greater China and Asia-Pacific Region, Shanghai Representative Office of Nycomed Pharma A/S
11:30-12:00
Registration and Market Landscape of Innovative Drugs (Southeast Asia)
Xu Na
3D Medicines, Director of Regulatory Affairs
12:00-12:30
Roundtable Discussion: Beginning with the End in Mind, Focusing on the Global Market: A Multi-Perspective Exploration of Pathways and Best Practices for the International Expansion of Innovative Drugs
*Agenda updated as of October 14; subject to change based on actual attendance.
Oct 31–Nov 1
@Crowne Plaza Shanghai Noah's Ark
Inviting You to Join the Pharmaceutical Feast👇👇
(Note: Please register with your real name to attend the conference; information is subject to review by the organizer.)
Exhibition Preview
June 24-26, 2025，CPHI & PMEC Chinawill be inShanghai Pudong New International Expo CenterOpening. We will continue to advance with the times, injecting sustained new momentum into China’s and the world’s pharmaceutical industries, and upholding our original aspiration and mission to jointly safeguard the security and stability of global industrial and supply chains, thereby promoting the healthy and sustainable development of the industry!
Currently,CPHI & PMEC China 2025 BoothHot Booking Now🔥Whether you are an established industry leader or an emerging innovator, we look forward to partnering with you to unlock business opportunities, achieve mutual growth, and shape the future together!
Scan the QR code now
Reserve Your Premium Spot
